Galaxy Medicare Makes Weak Debut with 5% Discount, Lists at ₹51.30 Against Poor Subscription Response

Galaxy Medicare Limited, the medical devices and surgical dressings manufacturer, made a disappointing debut on NSE SME on September 17, 2025. After closing its IPO bidding between September 10-12, 2025, the company commenced trading with a 5% discount at ₹51.30, significantly below the issue price of ₹54, reflecting weak investor confidence in the medical devices manufacturing sector amid challenging market conditions.

Galaxy Medicare Listing Details

Galaxy Medicare Limited launched its IPO at ₹54 per share with a minimum investment of 4,000 shares costing ₹2,16,000. The IPO received weak response with a subscription of just 1.83 times - retail investors at 2.10 times, NII at disappointing 1.48 times, and QIB at minimal 1.00 times, indicating limited investor interest across all categories with particularly poor institutional confidence in the medical devices business.

First-Day Trading Performance Outlook

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

• Listing Price: Galaxy Medicare share price opened at ₹54 and declined to ₹51.30 on NSE SME, representing a discount of 5% from the issue price of ₹54, delivering losses for investors and reflecting negative market sentiment towards the medical devices sector.

Growth Drivers and Challenges

Growth Drivers:

• Established Product Portfolio: Comprehensive range of medical devices including surgical dressings, POP bandages, adhesive tapes, compression bandages, and wound care solutions with 27 registered trademarks serving domestic and international markets.
• Quality Certifications: ISO 9001:2015 and ISO 13485:2016 certifications ensuring compliance with healthcare industry standards and acceptance by medical community including government health departments and corporate hospitals.
• Diversified Revenue Streams: Multiple business segments including flagship brand manufacturing, OEM services, institutional sales through government tenders on GEM Portal, and international exports providing revenue diversification.
• Strong Operational Metrics: Solid ROE of 19.88%, impressive ROCE of 22.38%, conservative debt-to-equity ratio of 0.25, healthy PAT margin of 8.60%, and robust EBITDA margin of 11.69% indicating efficient operations.

Challenges:

• Declining Profitability Trend: Revenue grew modestly by 9% to ₹40.27 crore in FY25 but PAT declined 9% to ₹3.37 crore, indicating margin pressure and operational challenges affecting business performance.
• Poor Market Reception: Weak listing performance with 5% discount and extremely low subscription of 1.83 times reflecting investor skepticism about valuation, growth prospects, and sector fundamentals.
• Small Scale Operations: Limited issue size of ₹22.31 crore and modest revenue base indicating restricted operational scale and competitive positioning against larger medical device manufacturers.
• Competitive Industry Dynamics: Medical devices sector facing intense competition from established players, regulatory complexities, and pricing pressures from government procurement affecting margin sustainability.

Utilisation of IPO Proceeds

• Capacity Enhancement: ₹4.89 crore for funding capital expenditure towards purchase of machinery for existing manufacturing facility at Bhubaneshwar, Odisha enhancing production capabilities.
• Working Capital: ₹8.94 crore for working capital requirements supporting inventory management, raw material procurement, and operational needs in medical devices manufacturing.
• General Corporate Purposes: Supporting business operations, strategic initiatives, and offer-related expenses for long-term growth and competitiveness.

Financial Performance of Galaxy Medicare

• Revenue: ₹40.27 crore for FY25, showing modest growth of 9% from ₹36.94 crore in FY24, reflecting steady but limited demand growth in medical devices sector.
• Net Profit: ₹3.37 crore in FY25, representing a decline of 9% from ₹3.71 crore in FY24, indicating margin pressure and operational challenges amid competitive market environment.
• Financial Metrics: Solid ROE of 19.88%, strong ROCE of 22.38%, conservative debt-to-equity ratio of 0.25, healthy PAT margin of 8.60%, robust EBITDA margin of 11.69%, and estimated market capitalisation of ₹81.93 crore.